Reactive oxygen species-mediated regulation of eNOS and iNOS expression in multicellular prostate tumor spheroids

Maria Wartenberg1, Maurice Schallenberg, Jürgen Hescheler

  • 1Department of Neurophysiology, University of Cologne, Cologne, Germany.

Insights

Nitric oxide (NO) protects prostate tumor spheroids from oxidative stress-induced apoptosis by scavenging reactive oxygen species (ROS). Lowering NO levels increases ROS and cell death, suggesting NO

Area of Science:

  • Oncology
  • Biochemistry
  • Cell Biology

Background:

  • Nitric oxide (NO) synthase isoforms, endothelial (eNOS) and inducible (iNOS), may influence prostate cancer development.
  • NO's role in inhibiting reactive oxygen species (ROS)-induced apoptosis is a key area of investigation.

Purpose of the Study:

  • To investigate the role of nitric oxide (NO) and reactive oxygen species (ROS) in DU-145 prostate tumor spheroid growth.
  • To elucidate the signaling pathways regulating eNOS and iNOS expression in response to oxidative stress.

Main Methods:

  • DU-145 prostate tumor spheroids were cultured and treated with various agents to modulate NO and ROS levels.
  • Expression levels of eNOS and iNOS were assessed.
  • NO production was measured using diaminofluorescein-2 diacetate (DAF-2DA).
  • Apoptosis was evaluated by measuring cleaved caspase-3 levels.

Main Results:

  • DU-145 spheroids produced both NO and ROS, with NO production decreasing as spheroid size increased.
  • eNOS expression decreased while iNOS expression increased with spheroid size, suggesting eNOS is the primary NO source.
  • Elevated ROS upregulated eNOS and downregulated iNOS, while epidermal growth factor (EGF) also increased eNOS in a redox-sensitive manner.
  • Inhibition of NO synthesis or scavenging NO increased ROS levels and induced apoptosis, indicating NO's protective role.

Conclusions:

  • Endogenous nitric oxide (NO) acts as a reactive oxygen species (ROS) scavenger in prostate tumor spheroids.
  • NO protects exponentially growing tumor spheroids from ROS-induced apoptosis, highlighting a potential therapeutic target.